Pharmaceuticals News & Press Release Distribution

Seegene unveils solutions to popularize molecular diagnostics at 2023 AACC

* Introduced syndromic quantitative PCR assays and a fully automated molecular diagnostic testing system, STARlet AIOS™ * Conducted symposium sessions on the usefulness of PCR testing in diagnosing gastrointestinal diseases * Participated in a presentation event for major Korean in-vitro dia...

2023-08-01 00:00 2600

Seegene unveils solutions to popularize molecular diagnostics at 2023 AACC

Fosun Health Capital reached a cooperation agreement with Medicilon to explore innovative drug research and development together

BOSTON, July 31, 2023 /PRNewswire/ -- On July 25, 2023, Fosun Health Capital established by Fosun Pharma (stock code:600196.SH), reached a strategic partnership with Medicilon (stock code: 688202.SH). Meanwhile StarMab Biology (Suzhou) (jointly invested by the innovation drug research fund of Fo...

2023-07-31 20:30 3272

Fosun Health Capital reached a cooperation agreement with Medicilon to explore innovative drug research and development together

111 to Announce Second Quarter 2023 Unaudited Financial Results on August 24, 2023 - Conference Call to Follow

SHANGHAI, July 31, 2023 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced that it will report its unaudited financial result...

2023-07-31 17:59 2634

Biosion Announces Phase II Study Start for Anti-TSLP mAb BSI-045B in Atopic Dermatitis (ADAMANT)

NEWARK, N.J. and NANJING, China, July 31, 2023 /PRNewswire/ -- Biosion USA, Inc. (Biosion), a global clinical-stage R&D biotechnology company, today announced the phase 2 study initiation for the evaluation of BSI-045B, an anti-TLSP mAb, in the treatment of atopic dermatitis (AD) . "We are pleas...

2023-07-31 17:05 4686

U.S. FDA Accepts Biologics License Application for GC Biopharma's GC5107B (Immune Globulin Intravenous (Human), 10% Liquid)

YONGIN, South Korea, July 31, 2023 /PRNewswire/ -- GC Biopharma (006280.KS), a global biopharmaceutical company dedicated to specialty plasma-derived therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's resubmission of the Biologics License App...

2023-07-31 13:20 2526

Transcenta Anti-sclerostin Monoclonal Antibody TST002 (Blosozumab) Received Approval from China CDE to Initiate Phase II Clinical Trial in Patients with Reduced Bone Mineral Density

SUZHOU, China, July 31, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that it has receiv...

2023-07-31 08:10 3264

Daewoong Pharmaceutical submits a new drug application for Fexuprazan in China challenging the world's largest market for anti-ulcer drugs

– Daewoong Pharmaceutical, "Expecting the smooth approval with the successful phase 3 clinical trial inChina aiming to reach 100 countries by 2027" SEOUL, South Korea, July 31, 2023 /PRNewswire/ -- Daewoong Pharmaceutical's domestically produced drug no. 34 Fexuprazan, a newly developed one for t...

2023-07-31 08:00 4367

Latest Updates of 7 Viva's Portfolio Companies

HONG KONG, July 28, 2023 /PRNewswire/ -- In the face of ever-changing circumstances, technological innovation remains the eternal driving force behind the long-term growth of biopharmaceutical companies. It continuously breathes life into these enterprises, enabling them to successfully transitio...

2023-07-28 19:31 8934

HANQUYOU Marks 3rd Anniversary with Brilliant Achievements

* HANQUYOU is the China-developed biosimilar with the most marketing approvals, covering 41 countries and regions * The launch of HANQUYOU kicks off the competition between Chinese pharmaceutical companies and the world's bio-pharmaceutical companies in biosimilar monoclonal antibodies * He...

2023-07-28 15:53 4964

HANQUYOU Marks 3rd Anniversary with Brilliant Achievements

* HANQUYOU is the China-developed biosimilar with the most marketing approvals, covering 41 countries and regions * The launch of HANQUYOU kicks off the competition between Chinese pharmaceutical companies and the world's bio-pharmaceutical companies in biosimilar monoclonal antibodies * He...

2023-07-28 15:27 3534

Wuan Ankang Hospital's Innovative Tumor Treatment Attracts Many Patients

HANDAN, China, July 28, 2023 /PRNewswire/ -- In Handan City, Hebei Province, China, the Wu'an Ankang Hospital has 35-year of experience with tumor treatment. It has now become a second-class general hospital. The reason it attracts many patients from bothChina and abroad is that they practice hol...

2023-07-28 14:35 1675

GILEAD LAUNCHES GLOBAL ALL4LIVER GRANT PROGRAM TO HELP ACHIEVE THE WORLD HEALTH ORGANIZATION'S GOAL OF VIRAL HEPATITIS ELIMINATION BY 2030

– Gilead expands the ALL4LIVER Grant, Providing Grant Funding to Organizations inAfrica, South America, Asia and Oceania, Europe and North America – – Themed 'Test. Link. Prioritize', the Grant Program will Target Projects Focusing on Viral Hepatitis Elimination by 2030 – SINGAPORE, July 28, ...

2023-07-28 12:00 6414

Sirnaomics Appoints Dr. Francois Lebel as Senior Vice President for Preclinical and Clinical Development

HONG KONG, Germantown, Md. and SUZHOU, China, July 28, 2023 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", Stock Code: 2257.HK, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, today announced tha...

2023-07-28 11:56 4067

61.6 percent of Young Thai Women Put off by Pap Smears: BGI Genomics Cervical Cancer Survey

* 61.6% of Thai women aged 21-25 years deterred by pap smears which is higher than the global average of 43.5% HONG KONG, July 28, 2023 /PRNewswire/ -- Only 28.5% of Thai women are diagnosed at stage I of cervical cancer when survival rates are highest, according to a study

2023-07-28 08:37 2073

61.6 percent of Young Thai Women Put off by Pap Smears: BGI Genomics Cervical Cancer Survey

HanAll Biopharma Reports Second Quarter 2023 Financial Results and Provides a Business Update

* Sales recorded KRW 41.4 billion, a 58 percent increase from the same period in 2022, due to sustained robust growth of major products in addition to milestone revenues from the progress in clinical programs of batoclimab. * Multiple clinical development milestones have been reached, includin...

2023-07-27 19:00 2705

Clarivate Enhances Patient Data Intelligence Solution with Addition of German Hospital Prescribing Insights

New data captures German prescribing insights providing researchers with aggregated, anonymised specialty prescribing habits across brands and diseases LONDON, July 27, 2023 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in connecting people and organizations to intelligence they ca...

2023-07-27 15:00 2361

AI Medical Service Inc. Signs Joint Research Agreement with Stanford Medicine

- AIM Is First Japanese Company to Establish Joint Research Agreement in Field of Endoscopic AI - TOKYO, July 27, 2023 /PRNewswire/ -- AI Medical Service Inc. (hereinafter AIM), a medical start-up specializing in the development of diagnostic endoscopic AI, has signed a joint research agreement ...

2023-07-27 14:00 1829

Acceptance Of Clinical Trial Application For The Recbio's Novel Adjuvanted Recombinant Shingles Vaccine REC610 In China And Overseas Clinical Trial Progress

TAIZHOU, China, July 27, 2023 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the"Board") is pleased to announce that the Group has recently received the notice of acceptance (acceptance number: CXSL2300518) issued by National Medical Products Administration ("NMPA"), pursuant to which the c...

2023-07-27 10:57 6992

Everest Medicines Announces Commercial Launch and First Prescription for XERAVA® in China

Everest transforms into a commercial-stage innovative biopharmaceutical company SHANGHAI, July 27, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicin...

2023-07-27 08:10 3816

YS Biopharma Announces Financial Results for Fiscal Year 2023 Ended March 31, 2023

Total revenues increase by 36.3% year-over-year; gross margin improves to 77.7%; balance sheet remains robust Company's PIKA rabies vaccine approved for Phase III clinical trials in Singapore, the Philippines, and Pakistan; interim results expected early next year GAITHERSBURG, Md., July 27, 20...

2023-07-27 05:00 5259